title: Multimodality treatment using AK-2123, hydralazine, radiation & hyperthermia on a transplantable mouse tumour.
abstract: The in vivo response of a transplantable mouse tumour, Sarcoma 180 to AK-2123 (AK), local irradiation (RT) and local hyperthermia, as influenced by a vasoactive drug, hydralazine (HDZ), was assessed on the basis of tumour cure (complete response CR), volume doubling time (VDT), regrowth delay (RD) and animal survival up to 120 days. A single ip injection of 200 mg/kg b.wt. AK produced more than 15 per cent CR. Combination of any two agents resulted in a better response than the single agent treatments. AK in combination with 43 degrees C, 30 min (HT) was more effective than HT combination with 10 Gy. The presence of 5 mg/kg HDZ, injected immediately after 5 Gy, in combination with AK increased the therapeutic effect over that produced by AK+10Gy. Combination of all the three agents (AK+10Gy+HT) produced 100 per cent CR and prolonged disease free animal survival. A similar response could be obtained by the presence of HDZ with a lower radiation dose of 5 Gy in combination with AK and HT (AK+5Gy+HDZ+HT). This multimodality treatment offers the possibility of further reduction in the doses of individual agents, and in the possible side effects on normal tissues without compromising the tumour cure effect.
authors.affiliation: Department of Radiobiology, Kasturba Medical College, Manipal.
authors.forename: B S
authors.initials: BS
authors.lastname: Rao
authors.forename: P U
authors.initials: PU
authors.lastname: Devi
mesh_terms: D000818:Animals; D003131:Combined Modality Therapy; D005260:Female; D006830:Hydralazine / Q000627:therapeutic use*; D006979:Hyperthermia, Induced; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy* / Q000628:therapy*; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D012513:Sarcoma, Experimental / Q000188:drug therapy / Q000532:radiotherapy* / Q000628:therapy*; D014230:Triazoles / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D011838:Radiation-Sensitizing Agents; D014230:Triazoles; D014665:Vasodilator Agents; C072690:AK 2123; D006830:Hydralazine